High-density lipoprotein proteomic composition, and not efflux capacity, reflects differential modulation of reverse cholesterol transport by saturated and monounsaturated fat diets

Circulation

Volumn 133, Issue 19, 2016, Pages 1838-1850

  O'Reilly, Marcella ^a   Dillon, Eugene ^a   Guo, Weili ^a   Finucane, Orla ^a   McMorrow, Aoibheann ^a   Murphy, Aoife ^a   Lyons, Claire ^a   Jones, Daniel ^a   Ryan, Miriam ^a   Gibney, Michael ^a   Gibney, Eileen ^a   Brennan, Lorraine ^a   De La Llera Moya, Margarita ^b   Reilly, Muredach P ^c,d   Roche, Helen M ^a   McGillicuddy, Fiona C ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cholesterol, HDL; inflammation; lipoproteins; obesity; proteome; reverse cholesterol transport

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; GLUCOSE; HAPTOGLOBIN; HEMOPEXIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MONOUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRIACYLGLYCEROL; FAT INTAKE; FATTY ACID;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; FECES; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; IN VIVO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIVER; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; TRIACYLGLYCEROL BLOOD LEVEL; ADMINISTRATION AND DOSAGE; ADOLESCENT; ADULT; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FAT INTAKE; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MOUSE; OBESITY; PHYSIOLOGY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BIOLOGICAL TRANSPORT; CHOLESTEROL; DIET, HIGH-FAT; DIETARY FATS; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; OBESITY; PROTEOMICS; YOUNG ADULT;

EID: 84963954530     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.020278     Document Type: Article

References (36)

1. Rader DJ, Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003 92 4A 42J 49J
2. Rader DJ, Effect of insulin resistance, dyslipidemia, and intra-Abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007 120 3 suppl 1 S12 S18. doi: 10.1016/j.amjmed.2007.01.003
3. Osborn O, Olefsky JM, The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012 18 363 374. doi: 10.1038/nm.2627
4. Hansson GK, Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 1685 1695. doi: 10.1056/NEJMra043430
5. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting JP, Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011 12 408 415. doi: 10.1038/ni.2022
6. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Mühleisen TW, Muhlestein JB, Münzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nöthen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schäfer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, März W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J, Samani NJ, Cardiogenics; CARDIoGRAM Consortium Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011 43 333 338. doi: 10.1038/ng.784
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109 2122. doi: 10.1056/NEJMoa0706628
8. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797
9. Nicholls SJ, Ruotolo G, Brewer HB, Kane JP, Wang MD, Krueger KA, Adelman SJ, Nissen SE, Rader DJ, Cholesterol efflux capacity and pre-Beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol 2015 66 2201 2210. doi: 10.1016/j.jacc.2015.09.013
10. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW, Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007 117 746 756. doi: 10.1172/JCI26206
11. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM, Antiinflammatory properties of HDL. Circ Res 2004 95 764 772. doi: 10.1161/01.RES.0000146094.59640.13
12. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC, Proteomic analysis of high-density lipoprotein. Proteomics 2006 6 721 730. doi: 10.1002/pmic.200500191
13. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011 364 127 135. doi: 10.1056/NEJMoa1001689
14. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH, Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003 23 712 719. doi: 10.1161/01.ATV.0000057572.97137.DD.
15. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP, Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009 119 1135 1145. doi: 10.1161/CIRCULATIONAHA.108.810721
16. Vikari J, Precipitation of plasma lipoproteins by PEG-6000 and its evaluation with electrophoresis and ultracentrifugation. Scand J Clin Lab Invest 1976 36 265 268. doi: 10.1080/00365517609055259
17. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ, Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007 117 2216 2224. doi: 10.1172/JCI32057
18. Ryan MF, O'Grada CM, Grada CO, Morris C, Segurado R, Walsh MC, Gibney ER, Brennan L, Roche HM, Gibney MJ, Within-person variation in the postprandial lipemic response of healthy adults. Am J Clin Nutr 2013 97 261 267. doi: 10.3945/ajcn.112.047936
19. Finucane OM, Lyons CL, Murphy AM, Reynolds CM, Klinger R, Healy NP, Cooke AA, Coll RC, McAllan L, Nilaweera KN, O'Reilly ME, Tierney AC, Morine MJ, Alcala-Diaz JF, Lopez-Miranda J, O'Connor DP, O'Neill LA, McGillicuddy FC, Roche HM, Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity. Diabetes 2015 64 2116 2128. doi: 10.2337/db14-1098
20. Zhang Y, McGillicuddy FC, Hinkle CC, O'Neill S, Glick JM, Rothblat GH, Reilly MP, Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 2010 121 1347 1355. doi: 10.1161/CIRCULATIONAHA.109.897330
21. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL, Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008 299 1265 1276. doi: 10.1001/jama.299.11.1265
22. Shih DM, Lusis AJ, The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol 2009 20 288 292. doi: 10.1097/MOL.0b013e32832ca1ee.
23. Chait A, Han CY, Oram JF, Heinecke JW, Thematic review series: the immune system and atherogenesis. Lipoprotein-Associated inflammatory proteins: markers or mediators of cardiovascular disease?. J Lipid Res 2005 46 389 403. doi: 10.1194/jlr.R400017-JLR200
24. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, Fogelman AM, Reddy ST, Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 2009 284 18292 18301. doi: 10.1074/jbc.M109.017202
25. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, Kontush A, Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004 89 4963 4971. doi: 10.1210/jc.2004-0305
26. Farbstein D, Levy AP, HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther 2012 10 353 361. doi: 10.1586/erc.11.182
27. Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, Kaminski WE, Schmitz G, Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 1999 257 29 33. doi: 10.1006/bbrc.1999.0406
28. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P, A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001 7 161 171
29. Gillotte KL, Lund-Katz S, de la Llera-Moya M, Parks JS, Rudel LL, Rothblat GH, Phillips MC, Dietary modification of high density lipoprotein phospholipid and influence on cellular cholesterol efflux. J Lipid Res 1998 39 2065 2075
30. Buonacorso V, Nakandakare ER, Nunes VS, Passarelli M, Quintão EC, Lottenberg AM, Macrophage cholesterol efflux elicited by human total plasma and by HDL subfractions is not affected by different types of dietary fatty acids. Am J Clin Nutr 2007 86 1270 1277
31. Favari E, Ronda N, Adorni MP, Zimetti F, Salvi P, Manfredini M, Bernini F, Borghi C, Cicero AF, ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects. J Lipid Res 2013 54 238 243. doi: 10.1194/jlr.P030452
32. Briand F, Thiéblemont Q, Muzotte E, Sulpice T, High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters. J Nutr 2012 142 704 709. doi: 10.3945/jn.111.153197
33. Mensink RP, Zock PL, Kester AD, Katan MB, Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-Analysis of 60 controlled trials. Am J Clin Nutr 2003 77 1146 1155
34. Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW, Castelli WP, Schaefer EJ, LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb 1992 12 1410 1419
35. Krauss RM, Dreon DM, Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men. Am J Clin Nutr 1995 62 478S 487S
36. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM, Meta-Analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr 2010 91 535 546. doi: 10.3945/ajcn.2009.27725